ERBB2 and breast cancer: Monitoring HER2 immunocytochemically using the CellSearch System® revealed CTC-specific acquisition of HER2 overexpression in 18% of patients (8/45) with advanced BC undergoing anti-HER2 trastuzumab treatment [208].